Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

Exclusion Criteria

• •1. Patients receiving prior treatment in the study eye with verteporfin, any focal laser photocoagulation, vitrectomy, or intravitreous injection of antiangiogenic medications, including triamcinolone, pegaptanib, bevacizumab, or ranibizumab.
• •2. Neovascular membrane from any other retinal disease such as myopic degeneration, histoplasmosis, retinal angiomatous proliferation, or other ocular inflammatory disease.
• •3. Choroidal neovascular membrane greater than 9 disc diameters in size.
• •4. Previous posterior vitrectomy in the study eye.
• •5. Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period.
• •6. Pregnant women or premenopausal women not using adequate contraception.
• •7. History of allergy to fluorescein, Visudyne, Lucentis.
• •8. Inability to comply with study or follow up procedures.